SAMAR CCC

(Name)
(University)
Executive summary

Biosantee wants to launch SAMAR CCC

This antimicrobial resistance medicine is a replacement to antibiotics
SAMAR CCC has to pass all the four phases of FDA approval
Its target market is in North America
Projected profits is US$ 2 billion for the first 2 years
Description of business

Biosantee is a private company located in Trenton, New Jersey

It deals with antibiotics and has been in operation for more than 20 years
It adopts a sophisticated five-phase business model
Mission & Vision

Mission
To be the worlds most acknowledgeable and well committed company to its
patients, customers, colleagues, investors, business partners, and communities
where it delivers its services
Vision
Dedication to to humanitys quest for longer, healthier, happier lives through
innovation in pharmaceutical and health products
Product description

SAMAR CCC is an antimicrobial resistance medicine

Its is expected to replace antibiotics
It is derived from two molecules
Has undergone all phases of FDA approval
Industrial Analysis

Pharmaceutical industry is worth over 650 billions

90% of the industry is regulated
Largest market is in North America
Highest growth is experienced in European Union
Cont
Market Needs

Antibiotics are still essential

There is fear of the growth of antimicrobial resistance medicine
Antibiotics can be obtained over the counter
Trends and Challenges

Antibiotics are known to have severe side effects

Rise od antimicrobial medicine is threatening antibiotics
Effective medical treatment can replace antibiotics
Competitive analysis

Production of SAMAR CCC is less costly compared to the competition

Less cost of FDA approval
High chance of phase 1 and 2 approval waiver
Cont
Strategy and implementation

SAMAR CCC already patented in the U.S.

Wide distribution channels for the drug
Shortened marketing approval period
Marketing Plan

Product will replace antibiotics

Will be availed all over the globe
Will cost low compared to other similar drugs
Will be marketed using new technology
SWOT Analysis (Strengths)

Wide distribution channel for the company

Qualified and experienced team of scientists
A team of marketing and sales professionals
Own manufacturing plan
SWOT Analysis (Weaknesses,
Opportunities, and Threats)
Weaknesses: High cost of production and being a private entity
Opportunities: FDA approved, new markets, and use of technology
Threats: Davos Declaration
Product Launch

FDA Phases
Phase 1: Assessing drug safety
Phase 2: Testing efficacy of drug
Phase 3: Determining benefits and effects
Phase 4: Post marketing surveillance
Cont

Over the counter Phases

Phase 1: Screening
Phase 2: Preclinical pharmacology
Phase 3: Preclinical safety
Phase 4: Clinical pharmacology and safety
Phase 5: Approval
Projected P & L
Projected 5-year Profit and Loss

"in Millions"

Year 1 Year 2 Year 3 Year 4 Year 5

Revenue 4510 5520 5610 5690 5740

Cost of Sales 3150 3690 4020 3810 3940

Gross profit/Loss 1360 1830 1590 1880 1800

Operating expenses 1060 1020 1200 960 840

Income/Loss 300 810 390 920 960

Projected Balance Sheet
Projected 5-year Balance Sheet

"in millions"
Year 1 Year 2 Year 3 Year 4 Year 5
Assets
Current Assets 30300 31310 26140 24920 25180

Fixed Assets 85000 85000 90000 92000 92000

Total Assets 115300 116310 116140 116920 117180

Liability and Shareholders Equity
Liabilities 65000 65500 65750 66000 66220

shareholders' equity 50000 50000 50000 50000 50000

Retained earnings 300 810 390 920 960

Total Liabilities and shareholder's equity 115300 116310 116140 116920 117180
Profitability chart

Biosantee Chem Profitability

1200

1000

800

600

400

200

0
1 2 3 4 5